- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04715906
Project COPE (Coping Options for Parent Empowerment)
April 26, 2022 updated by: Jill May Ehrenreich, University of Miami
Coping Options for Parent Empowerment
The purpose of this research study is to collect information to better understand caregiver responses to COVID-19 stress and to help caregivers of children with Autism Spectrum Disorder (ASD) cope with these stressors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be willing to consent to participate via RedCap
- Indicate a mild or greater elevation on screening measures of anxiety and/or depression
- Not meet any exclusion criteria.
- Lives in Florida
- Has a child between the ages of 4-13 years who has been diagnosed with ASD
- Speaks either English or Spanish primarily
- Has technical capacity to participate in Zoom sessions on a mobile device or preferably a computer
Exclusion Criteria:
- Severe mental illness (e.g., bipolar disorder, schizophrenia, an intellectual disability, psychosis, alcohol use disorder, substance use disorder) or hospitalization for mental health concerns or suicide attempt. Parents may receive concurrent psychiatric or psychological intervention services but may be excluded if the severity of current mental illness is such that outpatient, weekly group treatment would be considered inappropriate.
- Parents who report any prior arrest for child endangerment, child abuse or child neglect may also be excluded.
- Parents who have Moderate or greater risk of suicidal ideation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UP-Caregiver Group
Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
|
The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes.
The sessions will focus on a variety of Cognitive Behavior Therapy techniques.
These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Anxiety levels as measured by GAD-7
Time Frame: Baseline, 6 Weeks
|
Parent Psychopathology levels will be reported as the change in the Generalized Anxiety Disorder 7-item (GAD-7) scores.
GAD-7 is a 7-item measure assessing the presence and severity of symptoms of anxiety.
The Scale has a total score ranging from 0 to 21 with the higher scores indicating greater anxiety.
|
Baseline, 6 Weeks
|
Change in depressive symptoms as measured by the PHQ
Time Frame: Baseline, 6 Weeks
|
Parent Psychopathology levels will be reported as the change in the Patient Health Questionnaire (PHQ) scores.
PHQ is a 9-item measure assessing the severity of depressive symptoms.
It has a total score ranging from 0 to 27 with the higher scores indicating greater depressive symptoms.
|
Baseline, 6 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in parenting beliefs as measured by the PSOC Scale
Time Frame: Baseline, 6 Weeks
|
Parenting Sense of Competence (PSOC) scale is a 17-item measure of parenting self-efficacy and satisfaction.
It has a total score ranging from 17 to 102 with the higher scores indicating greater self-efficacy and satisfaction in the parenting role.
|
Baseline, 6 Weeks
|
Change in Hope as measured by the State Hope Scale
Time Frame: Baseline, 6 Weeks
|
State Hope Scale is a 6-item measure designed to evaluate hope in adults.
It has a total score ranging from 6 to 48 with the higher scores representing higher hope levels.
|
Baseline, 6 Weeks
|
Acceptability of Intervention as measured by the Program Feedback Scale
Time Frame: 6 Weeks
|
The Program Feedback Scale has a total score ranging from 0 to 28 with the higher score indicating perceived acceptability and feasibility of the program.
|
6 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2021
Primary Completion (Actual)
January 26, 2022
Study Completion (Actual)
February 16, 2022
Study Registration Dates
First Submitted
December 29, 2020
First Submitted That Met QC Criteria
January 14, 2021
First Posted (Actual)
January 20, 2021
Study Record Updates
Last Update Posted (Actual)
April 27, 2022
Last Update Submitted That Met QC Criteria
April 26, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20201530
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on UP-Caregiver
-
Northwestern UniversityNational Institute on Aging (NIA)Active, not recruitingCognitive Impairment | Alzheimer DiseaseUnited States
-
US Department of Veterans AffairsCompleted
-
Eunice Kennedy Shriver National Institute of Child...Autism SpeaksCompletedAutism Spectrum DisorderUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Secondary... and other conditionsUnited States
-
University of MiamiNational Institute on Disability, Independent Living, and Rehabilitation...CompletedCardiovascular Diseases | Obesity | Spinal Cord InjuryUnited States
-
University of Alabama at BirminghamUnited States Department of DefenseCompletedDementia | Traumatic Brain InjuryUnited States
-
Johns Hopkins UniversityNational Institute of Nursing Research (NINR)Completed
-
VA Office of Research and DevelopmentThe VA Western New York Healthcare SystemRecruiting
-
Duke UniversityCompletedCaregiver WellbeingUnited States
-
University of ZimbabweNational Institutes of Health (NIH)Completed